Paragon Care (ASX:PGC): How Are FY26 Healthcare Distribution Results Shaping Its Next Steps?

Aditi Sarkar

06 November 2026 02:04 AM AEDT

Paragon Care (ASX:PGC): How Are FY26 Healthcare Distribution Results Shaping Its Next Steps?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 underlying Revenue was reported at approximately AUD 3.7 billion.
FY26 underlying EBITDA reached AUD 97.2 million, with Underlying Profit after tax of AUD 26 million.
The group completed key stages of its integration programme during 2026.
Its healthcare distribution and Supply operations serve customers across Asia Pacific.

Paragon Care Limited (ASX:PGC) supplies pharmaceuticals, healthcare equipment, diagnostics, medical devices and consumables through wholesale, distribution and related operations across Asia Pacific. Its FY26 reporting covered progress integrating operations, expanding product categories and managing the financial demands of a large healthcare distribution network. On 5 November 2026, Paragon Care shares closed at AUD 0.155. The group’s Earnings measures, distribution infrastructure and working-capital commitments provide different perspectives on its operating performance.

Healthcare Distribution and Operating Structure

ParagonCare supplies pharmacies, hospitals, aged-care providers and other healthcare customers. Product categories include prescription pharmaceuticals, medical consumables, clinical equipment, diagnostic products and complementary medicines. The company operates across Australia and parts of Asia, which means procurement, distribution and supplier relationships span multiple markets. These activities can generate substantial sales relative to profit because pharmaceutical wholesale includes high product-throughput volumes and relatively narrow margins. Service reliability, inventory availability and supplier payment terms are therefore central to results. Paragon Care Limited (ASX:PGC) reported work during 2026 to complete its integration programme and simplify its operating model. The integration programme is relevant to how the Business consolidates distribution systems and support functions, rather than evidence of a guaranteed earnings improvement.

FY26 Results and Earnings Measures

For the year ended 30 June 2026, the company reported approximately AUD 3.7 billion in underlying revenue, underlying EBITDA of AUD 97.2 million and underlying net profit after tax of AUD 26 million. These figures are identified as underlying measures and must not be presented as equivalent to statutory net profit. During the first half of FY26, revenue was approximately AUD 1.905 billion, up 2.9% year on year, while underlying EBITDA was AUD 49.0 million, up 3.1%. First-half underlying net profit after tax reached AUD 13.3 million. The company also reported material adjustments in that half, including a provision concerning receivables from a pharmacy group. For Paragon Care Limited (ASX:PGC), the distinction between statutory outcomes and adjustments is important when considering cash collection, recurring margins and the quality of earnings.

Integration, Investment and Financial Discipline

The 2026 operating programme included progression of the group’s distribution infrastructure, including commencement of operations at its purpose-built Willawong distribution centre in Brisbane. Investments in facilities and systems are intended to improve the organisation of inventory and service delivery, but the effect on profitability depends on costs, utilisation and execution. The group also disclosed Acquisition and investment activity during FY26, expanding geographic and product exposure. Acquisition consideration, integration expenditure and changes in working Capital can affect Liquidity even when revenue increases. Its February 2026 half-year release reported net Debt of AUD 287.5 million at 31 December 2025. This was a balance-sheet position from that reporting date, not a current-day estimate. Paragon Care Limited (ASX:PGC) must manage operating cash generation alongside investment and debt servicing requirements.

Risks and 2026 Monitoring Points

Pharmaceutical and medical distribution are exposed to supplier concentration, contract renewals, regulatory compliance and changes in procurement demand. Inventory management matters because products may have expiry dates, temperature controls or specialised storage requirements. The company’s 2026 results also highlighted receivable collection risk, which can affect statutory earnings and cash conversion independently of reported sales. The board announced an on-market buy-back in September 2026, adding another capital-allocation decision to the company’s investment programme. For Paragon Care Limited (ASX:PGC), future reporting points include statutory profit reconciliation, working-capital movements, net debt, Cash Flow and evidence that completed integration work is improving operating efficiency. Any proposed growth initiatives must be assessed against the cash cost of implementation.

Key Insights

Paragon Care Limited (ASX:PGC) reported substantial FY26 distribution revenue and positive underlying earnings alongside integration work, infrastructure investment and balance-sheet requirements. Future results will help establish whether cash conversion and statutory profitability develop consistently with the reported underlying performance. Credit exposure, debt and supplier operations remain important monitoring factors.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.